Photo: GE Healthcare
Nov. 17, 2025 — GE HealthCare has announced that Cardiovascular Associates of America (CVAUSA) plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.
The pilot at Cardiovascular Medicine provided cardiologists with an opportunity to evaluate Flyrcado in real-world workflows. “The pilot demonstrated that Flyrcado can be seamlessly integrated into a high-volume cardiac PET practice,” said Dr. Edmund Coyne, former president of Cardiovascular Medicine. “In our Davenport location, we routinely perform 12+ cardiac PET scans a day, and during our two-week, 21 patient pilot, we found that Flyrcado fits smoothly into that workflow without disruption. We saw firsthand the benefits in diagnostic confidence and efficiency, as well as excellent image quality, and we look forward to seeing these advantages scaled across CVAUSA’s network.”
“Our mission is to deliver the highest quality cardiovascular care, and expanding the use of advanced cardiac PET imaging is a key part of that,” said Tim Attebery, chief executive officer of CVAUSA. “We perform approximately 85,000 cardiac PET procedures annually across our network, and following a successful pilot with Flyrcado, we’re excited to bring this technology to more of our sites — helping our partner cardiologists make more informed decisions for patients with known or suspected coronary artery disease.”
“We are encouraged by the adoption of Flyrcado in a variety of real-world settings — including large academic institutions, integrated delivery networks (IDNs), mobile PET/CT settings and customers transitioning from SPECT to PET MPI,” said Eric Ruedinger, vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada. “The accumulating real-world evidence shows Flyrcado’s versatility and efficacy across diverse clinical environments, laying the foundation for continued growth and confidence in this game-changing tracer.”
Recent milestones underscore the growing importance of Flyrcado in clinical practice. GE HealthCare announced a distribution and services agreement with CDL Nuclear Technologies to support implementation across multiple sites of care, including private cardiology practices. In addition, Flurpiridaz F 18 is now featured in a new international procedure standard co‑published by leading societies — SNMMI, ASNC, EANM and ACNM — in The Journal of Nuclear Medicine1 and Journal of Nuclear Cardiology. These guidelines highlight Flurpiridaz F 18 high myocardial uptake, almost linear extraction fraction relationship, and superior spatial resolution compared to SPECT and outline best practices for patient selection, rest/stress protocols and workflow integration — further validating the tracer’s role in delivering high‑quality, safe and effective cardiac PET imaging.
1. Packard, R. R. S., Maddahi, J., Pelletier-Galarneau, M., Al-Mallah, M. H., Coelho, M., Dorbala, S., Galt, J., Hyun, M., Menon, N., Miller, E. J., Shetty, M., & Saraste, A. (2025). SNMMI/EANM/ASNC/ACNM procedure standard/practice guideline for 18F-flurpiridaz PET myocardial perfusion imaging and blood flow quantitation. Journal of Nuclear Medicine and Journal of Nuclear Cardiology. https://doi.org/10.2967/jnumed.125.270873
January 16, 2026 
